Veröffentlichungen
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. M. Eichelbaum, L. Bertilsson, J. Säwe und C. Zekorn: In: Clinical Pharmacology and Therapeutics. 31, 1982, S. 184–186.
Populationsgenetische und Familienuntersuchung zum Polymorphismus des Spartein- und Debrisoquinmetabolismus; Zekorn C, Dissertationsschrift 1983, Rheinische Friedrich Wilhelms Universität Bonn
Pharmacokinetics of metoprolol in relation to polypmorphic spartein oxidation; Kirch W, Ohnhauss EE, Zekorn C, Eichelbaum M, Arch Toxicol 1985
Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation ; Zekorn C, Achert G, Hausleiter HJ, Moon CH, Eichelbaum M; J molecular medicine , Vol. 63 (22. 1985), p. 1180-1186
Pharmacokinetics of midazolam in relation to polymorphic spartein oxidation. Klotz U, Mukus G, Zekorn C, Eichelbaum M; Br.J.Clin Pharm, 22, 618-619 (1986)
The genetic polymorphism of sparteine metabolism, M. Eichelbaum, K.-P. Reetz, E. K. Schmidt and C. Zekorn , J Xenobiotic 1986, Vol. 16, No. 5 , Pages 465-481
The influence of enzyme induction on polymorphic spartein oxidation; Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C; Br.J Clin Pharm, 22 (1); 1986 49-55
Chromosomal assignment of human cytochrom P-450 (debrisoquin/sparteine type) to chromosome22. M. Eichelbaum, M.P. Baur, H.J. Dengler, B.O. Osikowska-Evers, G. Tieves, C. Zekorn und C. Rittner:British Journal of Clinical Pharmacology. 23, 1987, S. 455–458
Genetischer Polymorphismus des Propafenon Metabolismus; Trenk D, Wagner F, Jähnchen E, Eichelbaum M, Zekorn C, Harnasch P, Hauf G, Rosskamm H, Z Kardio (Supp 1) 76:81; (1987)
Acute haemodynamic effects of i.v.nitrendipine in healthy subjects; Mikus G, Zekorn C, Brecht T, Eichelbaum M, Europ J Clin Pharm 41,2, 99-103 (1991)
Pharmocokinetics amd metabolism of quinidine in extensive and poor metabolizers of spartein ; Mikus G, Ha HR, Vozeh S, Zekorn C, Follath F, Eichelbaum M; Eur J clin Pharm 4 1991) 99-103
One-Week Once-Daily Triple Therapy with Esomeprazole, Moxifloxacin, and Rifabutin for Eradication of Persistent Helicobacter pylori Resistant to Both Metronidazole and Clarithromycin. Stephan Miehlke, Wulf Schneider-Brachert, Christian Kirsch, Andrea Morgner, Ahmed Madisch, Eberhard Kuhlisch, Christian Haferland, Elke Bästlein, Claus Jebens, Christoph Zekorn, Holger Knoth, Manfred Stolte, Norbert Lehn; Helicobacter 2008 Feb ;13 (1): 69-74
Randomisierte Multicenterstudie zur Effektivität und Verträglichkeit von Esomeprazol, Moxifloxacin und Amoxicillin in der Reservetherapie der Helicobacter pylori Infektion; Berning M, Krasz S, Schneider-Brachert W, Madisch A, Laass M, Knoth H, Kulisch E, Neumeyer M, Jebens C, Zekorn C, Jacobs E, Vieth M, Stolte M, Morgner A, Miehlke S, Z Gastro 2009; 47 P011
Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Stephan Miehlke, Susanne Krasz, Wulf Schneider-Brachert, Eberhard Kuhlisch, Marco Berning, Ahmed Madisch, Martin W Laass, Michael Neumeyer, Claus Jebens, Christoph Zekorn, Holger Knoth, Michael Vieth, Manfred Stolte, Norbert Lehn, Andrea Morgner Helicobacter. 2011 Dec: 16(6):420-426
Randomized Trail on 14 versus 7 days of Esomeprazol, Moxifloxacin, and Amoxicillin for Second-line or Rescue Treatment of Helicobacter pylori Infection; Miehlke S, Krasz S, Schneuder-Bracxhert W, Kuhlisch E, Berning M, Madisch A, Laass M, Neumeyer M, Jebens C, Zekorn C, Knoth H, Vieth M, Stolte M, Lehn N, Morgner A; Z Gastro 2011; 49 – P003
Bridging the Gap between Research and Patient Care C O N T E N T S Certified w w w . b r e a s t c a n c e r u p d a t e . c o m DR GEORGE SLEDGE SUPPLEMENT D R N E I L L O V E : Welcome to Breast Cancer Update. This is Dr Neil Love. The last San Antonio Breast Cancer Symposium contained a wealth of new clinical research information that is of immediate practical relevance to oncolog